These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 11193299)

  • 1. [A randomized long-term comparative study of clinical efficacy of alpha 1-blocker with or without antiandrogen therapy for benign prostatic hyperplasia: focusing on improvement of I-PSS].
    Ohtani M; Kikuchi K; Tsuchiya A; Noguchi R; Akaza H; Kondo F; Koiso K
    Hinyokika Kiyo; 2000 Nov; 46(11):791-7. PubMed ID: 11193299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical efficacy and reduction effect on prostatic volume of chlormadinone acetate combined with tamsulosin hydrochloride in benign prostatic hyperplasia patients insufficiently treated with tamsulosin hydrochloride only].
    Ueki O; Kawaguchi K; Katsumi T; Murayama K; Kameda K; Nishino A; Sakai A; Haginaka T; Miyazaki K; Asari T; Egawa M
    Hinyokika Kiyo; 1998 Aug; 44(8):565-73. PubMed ID: 9783192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
    Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
    Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
    Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.
    Palacio A; Hernández C; Marqués A; Prats J; Espinosa FJ
    Arch Esp Urol; 2004 May; 57(4):451-60. PubMed ID: 15270291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urodynamic evaluation of alpha-1 blocker tamsulosin on benign prostatic hyperplasia using pressure-flow study].
    Miyatake R; Park YC; Koike H; Ohnishi N; Sugiyama T; Kurita T; Esa A; Kiwamoto H
    Nihon Hinyokika Gakkai Zasshi; 1996 Aug; 87(8):1048-55. PubMed ID: 8831212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University YM617 Study Group.
    Okada H; Kawaida N; Ogawa T; Arakawa S; Matsumoto O; Kamidono S
    Scand J Urol Nephrol; 1996 Oct; 30(5):379-85. PubMed ID: 8936627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial.
    Djavan B; Shariat S; Fakhari M; Ghawidel K; Seitz C; Partin AW; Roehrborn CG; Marberger M
    Urology; 1999 Feb; 53(2):251-9. PubMed ID: 9933035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporary intraurethral prostatic bridge-catheter compared with neoadjuvant and adjuvant alpha-blockade to improve early results of high-energy transurethral microwave thermotherapy.
    Djavan B; Ghawidel K; Basharkhah A; Hruby S; Bursa B; Marberger M
    Urology; 1999 Jul; 54(1):73-80. PubMed ID: 10414730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy.
    Kurita Y; Masuda H; Suzuki K; Fujita K; Kawabe K
    Br J Urol; 1997 Jul; 80(1):78-83. PubMed ID: 9240185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia].
    Hayashi T; Sakai Y; Saito K; Arai G; Hyochi N; Suzuki M; Masuda H; Kawakami S; Okuno T; Kobayashi T; Kageyama Y; Kihara K
    Hinyokika Kiyo; 2002 Jan; 48(1):7-11. PubMed ID: 11868386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
    Zlotta AR; Teillac P; Raynaud JP; Schulman CC
    Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.